Is dark chocolate healthier than milk chocolate? 2 dietitians explain 
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
U.S. Lifts Sanctions on Venezuelan Interim Leader Delcy Rodriguez Amid Diplomatic Shift 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Trump Administration Fires Immigration Judges Who Blocked Pro-Palestinian Student Deportations 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
Trump Expands Tariffs on Pharmaceuticals and Metals One Year After Liberation Day 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
SEC Approves FINRA Plan to Eliminate Pattern Day Trader Rules 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Vanda Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug tradipitant, branded as Nereus, marking the first new FDA-approved treatment for motion-induced vomiting in more than 40 years. The company announced that it plans to launch the drug in the United States in the coming months, a move that could significantly change the treatment landscape for motion sickness.
Motion-induced vomiting, often referred to as motion sickness, occurs when the brain receives conflicting signals from the eyes, inner ear, and body sensors. This condition commonly affects people during travel activities such as boating, driving, or flying and has long relied on older treatment options with limited innovation.
The FDA’s approval of Nereus was supported by two late-stage clinical trials involving a total of 681 patients. Results from these studies showed that tradipitant significantly reduced episodes of vomiting compared to placebo. The drug works by blocking a specific brain receptor associated with nausea and vomiting, offering a targeted and modern approach to treatment.
According to H.C. Wainwright analyst Raghuram Selvaraju, peak annual sales of tradipitant for motion sickness alone could exceed $100 million in the U.S., highlighting its strong commercial potential. Currently available motion sickness treatments include Viatris’ scopolamine patch Transderm Scop, WellSpring Pharmaceutical’s Bonine, and Prestige Consumer Healthcare’s Dramamine, many of which have been on the market for decades.
Tradipitant’s regulatory journey faced challenges in the past. In December 2018, the FDA placed a partial clinical hold on the drug, requesting additional long-term toxicity studies in dogs after classifying motion sickness as a chronic condition. However, the agency reversed its stance, reclassifying motion sickness as an acute condition and lifting the clinical hold on December 4, eliminating the need for further studies.
Vanda licensed tradipitant from Eli Lilly in 2012 and continues to study the drug for multiple indications, including gastroparesis and nausea linked to certain diabetes medications. The company has not yet disclosed pricing details for Nereus.
